Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 398 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: hemoglobin A1c Clear all

Conditions: Diabetes Mellitus, Type 1
Interventions: DREAM intervention; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years to 17 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Davis, California • Los Angeles, California • San Francisco, California

Conditions: Type 2 Diabetes
Interventions: Dapagliflozin, Dapagliflozin placebo, Metformin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 1,067 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 38
States / cities: Phoenix, Arizona • Tempe, Arizona • Fresno, California + 31 more

Conditions: Biomedical Technology, Type 1 Diabetes
Interventions: Medtronic 670G insulin pump; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 5 Years to 25 Years
Enrollment: 96 participants
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus Type 2
Interventions: GK Activator (2), Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 19
States / cities: Tucson, Arizona • Pine Bluff, Arkansas • Chula Vista, California + 16 more

Conditions: ESRD
Interventions: Not listed
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Staten Island, New York

Conditions: Type 1 Diabetes
Interventions: Care Ambassador Intervention, Psychoeducational Intervention; Behavioral
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 8 Years to 16 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes
Interventions: Denosumab, Placebo; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Birmingham, Alabama • Duarte, California • Indianapolis, Indiana

Conditions: Type 2 Diabetes
Interventions: ITCA 650 (exenatide in DUROS); Drug
Lead sponsor: Intarcia Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 51
States / cities: Birmingham, Alabama • Gulf Shores, Alabama • Chandler, Arizona + 44 more

Conditions: Type2 Diabetes Mellitus
Interventions: Faith-Based (FB, BHT DSMS), Faith-Placed (FP, Stanford DSMP); Behavioral · Other
Lead sponsor: The University of Texas at San Antonio; Other
Eligibility: 21 Years to 85 Years
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type2 Diabetes Mellitus
Interventions: Patient and/or Family Member Intervention, Certified Diabetes Educator Intervention, Physician Intervention, Front Desk Staff Intervention, Nurse Intervention; Behavioral
Lead sponsor: Georgia Institute of Technology; Other
Eligibility: 12 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Type 1 Diabetes
Interventions: Liraglutide, Placebo; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Williamsville, New York

Conditions: Diabetes Mellitus, Type 1
Interventions: EMR-based BPA model, Placebo (EMR-based without BPA model); Other · Behavioral
Lead sponsor: T1D Exchange, United States; Other
Eligibility: 2 Years to 95 Years
Enrollment: 1,178 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes Mellitus
Interventions: ASMART, Control Group; Behavioral · Other
Lead sponsor: KRJG Services Inc.; Other
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Warsaw, Indiana

Conditions: Diabetic Retinopathy
Interventions: Ketorolac 0.45% ophthalmic solution, Placebo - Preservative-free artificial tears, Aqueous PGE2 and inflammatory cytokines measurements; Drug · Other
Lead sponsor: Stephen J. Kim, MD; Other
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Prediabetes
Interventions: Dexcom Stelo CGM; Device
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Tampa, Florida

Conditions: Type 2 Diabetes
Interventions: Linagliptin, Basal Bolus, Linagliptin + 50% Glargine dose on discharge, Linagliptin + 80% Glargine; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 5
States / cities: Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 1 more

Conditions: Type 2 Diabetes, Insulin Resistance, Obesity, Metabolic Disease, PreDiabetes
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 14 Years to 18 Years
Enrollment: 175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hyperglycemia, Diabetes Mellitus, Pancreas Ductal Adenocarcinoma
Interventions: Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score, Abdominal imaging; Other
Lead sponsor: Pancreatic Cancer Action Network; Other
Eligibility: 50 Years to 85 Years
Enrollment: 8,869 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 2
States / cities: Pasadena, California • Houston, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK189075, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 65
States / cities: Mesa, Arizona • Artesia, California • Buena Park, California + 54 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1), Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2); Device
Lead sponsor: Boris Kovatchev, PhD; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Transplant; Complication, Rejection
Interventions: Allosure, AlloMap; Diagnostic Test
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Type 1 Diabetes
Interventions: FAM intervention consisting of a Follower of glucose data, Action Plan, and Remote Monitoring of glucose data, standard of care; Device · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetes Mellitus
Interventions: Enhanced CGM Interventions, Standard of Care; Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Type 2 Diabetes
Interventions: Mobile Health (mHealth) Patient-Reported Outcome (PRO) tool; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Device Use Reimagined Through Education And Mentorship

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

Analysis of Glycemic Control in Type 1 Diabetes Patients Using Hybrid Closed Loop Insulin Pump Therapy (Medtronic 670G)

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus

Correlation Between Glycated Hemoglobin and Mean Plasma Glucose in Hemodialysis Patients

Intensive Care Program for Youth With Diabetes

Denosumab for Type 1 Diabetes

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

Building a Healthy Temple: a Diabetes Self-management Support Program in Hispanic Faith Community Settings

Guide To Goals: A Novel Care Coordination Tool for Children With Type Two Diabetes (T2D)

Liraglutide in the Treatment of Type 1 Diabetes Mellitus

Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes

The Efficacy and Treatment Adherence With an Integrated Program on HbA1c Scores in Patients With Type 2 Diabetes

INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study

Pharmacist-Led Continuous Glucose Monitoring for Prediabetes

Linagliptin Inpatient Trial

Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents

Early Detection Initiative for Pancreatic Cancer

Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive

Improving Control and Reducing the Risk of Hypoglycemic Episodes in Type 1 Diabetes

Assessing Benchmarks For Allosure And Allomap Testing in Simultaneous Kidney & Pancreas Transplant Recipients.

FAM (Follower, Action Plan, and Remote Monitoring) Intervention to Reduce Severe Hyperglycemia in Adults With Type 1 Diabetes Mellitus at Risk for Diabetic Ketoacidosis

SPARK-CGM Implementation

Novel Digital Patient-Reported Outcomes Tool for Diabetes Management